Vlad Teodor Enciu

Dr. Vlad Teodor Enciu

"Carol Davila" University of Medicine and Pharmacy,, Bucharest, Bucureşti, Romania
orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 August 2024 in Diagnostics
Verified
Journal Article
Open access
PDF file
VEVlad Teodor Enciu
Vlad Teodor Enciu
POPRISCILA-MADALINA OLOGEANU
PRISCILA-MADALINA OLOGEANU
Carmen Fierbinteanu-BraticeviciCarmen Fierbinteanu-Braticevici
Carmen Fierbinteanu-Braticevici
Malnutrition frequently affects patients with alcoholic liver disease (ALD), with important impacts on disease prognosis. Sarcopenia, the clinical phenotype of malnutrition characterized by skeletal muscle loss, is the major component responsible for adverse events in this population. The aim of this study is to assess the use of ultrasound (US) skeletal muscle performance in stratifying ALD disease severity. We recruited 43 patients with ALD and divided them into two groups: alcoholic hepatitis (AH) and alcoholic cirrhosis (AC). We evaluated disease-specific clinical and biological parameters and their relation to US Rectus Femoris muscle (RFM) measurements, including RFM thickness, stiffness (RFMS) and echogenicity (RFE). A thirty-seconds chairs stand test (30sCST) was used as the sarcopenia surrogate test. RMF thickness correlated with platelet count and serum albumin (p < 0.001). Both RFM and RFMS correlated with disease severity (p < 0.001) and 30sCST (p < 0.001, p = 0.002). Patients with AH had more severe US muscle abnormalities compared to AC (RFMS 1.78 m/s vs. 1.35 m/s, p = 0.001) and the highest prevalence of RFE (χ2 = 8.652, p = 0.003). Rectus Femoris US assessment could represent a reliable tool in the diagnosis and severity stratification of ALD-induced sarcopenia.

24 November 2022 in Diagnostics
Verified
Journal Article
Open access
PDF file
Carmen Fierbinteanu-BraticeviciCarmen Fierbinteanu-Braticevici
Carmen Fierbinteanu-Braticevici
ACAna Calin-Necula
Ana Calin-Necula
VEVlad Teodor Enciu
Vlad Teodor Enciu
LGLoredana Gabriela Goran
Loredana Gabriela Goran
Anca StoianAnca Stoian
Anca Stoian
AMAlexandru Constantin Moldoveanu
Alexandru Constantin Moldoveanu
Background: The diagnosis of NASH needs a liver biopsy, an invasive procedure that is not frequently accepted by patients. The aim of our study was to evaluate the efficacy of the 13C-Octanoate breath test (OBT) as a non-invasive surrogate marker to differentiate patients with NASH from patients with simple steatosis (NAFL). Methods: We performed a prospective study on patients with histologically established non-alcoholic steatohepatitis and no other hepatic disease. Each patient underwent a testing protocol, which included a clinical exam, laboratory blood tests, standard abdominal ultrasound, and a 13C-Octanoate breath test. Results: The study group included: 82 patients with steatohepatitis, 64 patients with simple steatosis, and 21 healthy volunteers. The univariate and bivariate analysis identified that significant values were the percent dose recovery (PDR) at 15 min—r = 0.65 (AUROC = 0.902) and cumulative percent dose recovery (cPDR) at 120 min—r = 0.69 (AUROC = 0.899). Discussion: Our study showed that 13C-OBT had good efficacy for identifying patients with NASH from those with NAFL (steatosis alone) but not those with NAFL from healthy subjects. Considering all these pathogenic steps in NASH we considered that OBT could have the clinical utility to identify patients at risk for NASH, especially “fast progressors”.

10 March 2023 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
Carmen Fierbinteanu-BraticeviciCarmen Fierbinteanu-Braticevici
Carmen Fierbinteanu-Braticevici
VEVlad Teodor Enciu
Vlad Teodor Enciu
ACAna Calin-Necula
Ana Calin-Necula
IPIoana Raluca Papacocea
Ioana Raluca Papacocea
AMAlexandru Constantin Moldoveanu
Alexandru Constantin Moldoveanu
Background: While non-alcoholic fatty liver disease (NAFLD) is a wide-spread liver disease, only some patients progress towards steatohepatitis and cirrhosis. Aim: We comparatively analyzed the methacetin breath test (MBT) for the microsomal function of the liver and the octanoate breath test (OBT) for mitochondrial activity, in detecting patients with steatohepatitis and estimating fibrosis. Methods: 81 patients with histologically proven NAFLD (SAF score) were evaluated. The parameters used for both breath tests were the dose/h and the cumulative dose recovery at multiple timepoints. The statistical association between histological diagnosis and breath test results used Independent Samples t Test. The accuracy for diagnosis was evaluated using area under the receiver operator characteristic (AUROC) and the sensitivity and specificity were assessed using the Youden J method. Results: Both MBT and OBT were able to differentiate patients with simple steatosis from NASH and to stratify patients with significant fibrosis and cirrhosis (p-values < 0.001 for most analyzed timepoints). The best parameter for NASH diagnosis was OBT dose at 30 min. In the case of significant fibrosis, the most accurate test was MBT cumulative dose at 30 min. Conclusions: Both MBR and OBT tests are potentially useful tools in assessing patients with NAFLD.

18 July 2026 in Diagnostics
Verified
Journal Article
Open access
PDF file
Camelia Croitoru( Oprea)Camelia Croitoru( Oprea)
Camelia Croitoru( Oprea)
VEVlad Teodor Enciu
Vlad Teodor Enciu
CCCatalin Copaescu
Catalin Copaescu
Carmen Fierbinteanu-BraticeviciCarmen Fierbinteanu-Braticevici
Carmen Fierbinteanu-Braticevici
Background and Aims: Metabolic dysfunction-associated steatotic liver disease (MASLD) is the most prevalent chronic liver disease and frequently improves after bariatric surgery. Conventional postoperative follow-up is mainly based on weight-loss outcomes, such as Body Mass Index (BMI), excess weight loss (EWL), total weight loss (TWL), and routine biochemical parameters, which may not fully characterize hepatic fat response. Ultrasound-derived fat fraction (UDFF) provides a quantitative non-invasive assessment of hepatic steatosis, while DXA-derived visceral adipose tissue (VAT) reflects central adiposity and metabolic risk. This study aimed to evaluate whether combined UDFF and DXA-VAT assessment provides complementary information to conventional bariatric follow-up parameters after bariatric surgery. Methods: We conducted a prospective longitudinal cohort study on 41 patients with severe obesity who underwent bariatric surgery between July 2025 and May 2026. Anthropometric, body composition, metabolic, hepatic, and biochemical parameters were assessed at baseline (T0) and 6 months postoperatively (T1). UDFF, utilizing a DAX ultrasound transducer, was used for hepatic steatosis assessment, while DXA was performed for VAT, android fat mass, total body fat percentage, and lean mass quantification. Correlation analyses, multivariable linear regression, and an exploratory clinical discordance analysis were performed. Results: At 6 months after surgery, patients showed significant improvements in body weight, visceral adiposity, insulin resistance, biochemical parameters, and hepatic steatosis. VAT reduction showed the strongest association with UDFF reduction, whereas conventional weight-loss outcomes, anthropometric, and metabolic parameters did not fully identify patients with residual steatosis. These findings suggest that hepatic fat improvement after bariatric surgery is more closely related to changes in visceral adiposity than to weight loss alone. Conclusions: Combined UDFF and DXA-derived VAT assessment may provide a practical dual-compartment imaging framework for postoperative MASLD monitoring. This approach captures both hepatic fat response and visceral adiposity remodeling, offering information that complements conventional bariatric follow-up based on weight-loss outcomes.

21 October 2023
Verified
Book Chapter
Closed access
PDF file
CFCarmen Fierbinteanu-Braticevici
Carmen Fierbinteanu-Braticevici
VEVlad Teodor Enciu
Vlad Teodor Enciu

26 September 2026 in Diagnostics
Verified
Journal Article
Open access
PDF file
Carmen Fierbinteanu-BraticeviciCarmen Fierbinteanu-Braticevici
Carmen Fierbinteanu-Braticevici
POPRISCILA-MADALINA OLOGEANU
PRISCILA-MADALINA OLOGEANU
CCCristian Ionut Costin
Cristian Ionut Costin
ACANDREI COZEA
ANDREI COZEA
VEVlad Teodor Enciu
Vlad Teodor Enciu
Background: Alcohol-associated hepatitis (AH) is an acute inflammatory phenotype of alcohol-associated liver disease associated with substantial short-term mortality. Established clinical scores quantify disease severity but do not directly characterize liver tissue mechanics. Ultrasound-derived viscosity-related measurements may provide complementary, non-invasive information on viscoelastic tissue behavior, although their biological determinants remain incompletely defined. Objective: We aimed to evaluate the association between liver viscosity and AH through the Sound Touch Visco-elastography Imaging (STVi) parameter and inflammatory, biochemical, and MDF-defined severity measures, and to explore its discriminatory performance. Methods: This prospective, single-center, cross-sectional pilot study included 62 patients with clinically diagnosed AH and 30 healthy volunteers. Participants underwent multiparametric ultrasound assessment using the Resona A20 platform with STVi, liver stiffness measurement, and attenuation imaging. Results: The viscosity-related parameter was higher in patients with AH than in healthy volunteers and was associated with liver stiffness, inflammatory markers, and MDF-defined severity. The exploratory AH-versus-healthy comparison yielded an AUC of 0.873 (95% CI, 0.797–0.934). Within the AH cohort, 28 patients had severe AH (MDF ≥ 32) and 34 had non-severe AH. For MDF-defined severe AH, the AUC was 0.863 (bootstrap 95% CI, 0.756–0.955). At the Youden-derived cutoff of 2.8 Pa·s, sensitivity was 78.6% and specificity was 94.1%. Conclusions: STVi provides a model-derived, platform-dependent viscosity-related parameter associated with inflammatory measures and clinical severity in AH. These preliminary findings suggest that liver viscosity imaging may represent a valuable new avenue for the non-invasive assessment of AH. However, standardized acquisition, longitudinal assessment, histological correlation, and external validation are required before clinical implementation.